Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Sep;31(5):433-40.
doi: 10.1016/j.semnephrol.2011.08.007.

Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options

Wolfram Doehner  1 , Ulf Landmesser
Affiliations
Free article
Review

Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options

Wolfram Doehner et al. Semin Nephrol. 2011 Sep.
Free article

Abstract

The association between increased uric acid (UA) levels and cardiovascular disease (CVD) has been observed and studied for many decades. The value of UA as an independent factor within the metabolic risk profile for prediction of CVD in the normal population remains an issue of ongoing discussion. In turn, increasing evidence suggests that among patients with established CVD such as heart failure UA is an independent marker of disease state and prognosis. Increased UA levels may be an indicator of up-regulated activity of xanthine oxidase, a powerful oxygen radical-generating system in human physiology. Increased reactive oxygen species (ROS) accumulation contributes to endothelial dysfunction, metabolic and functional impairment, inflammatory activation, and other features of cardiovascular pathophysiology. Accordingly, inhibition of xanthine oxidase activity has been shown to improve a range of surrogate markers in patients with CVD, but this effect seems to be confined to hyperuricemic patients because disappointing results were reported in studies with normouricemic patients. In this review we summarize current evidence on hyperuricemia in CVD. The value of UA as a biomarker and as a potential therapeutic target for tailored metabolic treatment in CVD is discussed.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms